Pfizer (NYSE:PFE) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Pfizer (NYSE:PFE) in a research note released on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has a $27.00 target price on the biopharmaceutical company’s stock.

PFE has been the subject of a number of other research reports. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Bank of America dropped their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Zacks Research cut shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.06.

Pfizer Stock Performance

NYSE PFE opened at $26.83 on Wednesday. The company has a market capitalization of $152.55 billion, a price-to-earnings ratio of 19.73 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a fifty day simple moving average of $25.57 and a 200 day simple moving average of $25.07.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 EPS. Sell-side analysts expect that Pfizer will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. Shell Asset Management Co. grew its holdings in shares of Pfizer by 61.6% during the second quarter. Shell Asset Management Co. now owns 89,658 shares of the biopharmaceutical company’s stock valued at $2,173,000 after buying an additional 34,178 shares during the last quarter. Canopy Partners LLC grew its holdings in shares of Pfizer by 5.9% during the second quarter. Canopy Partners LLC now owns 36,618 shares of the biopharmaceutical company’s stock valued at $888,000 after buying an additional 2,024 shares during the last quarter. Finally, BankPlus Trust Department increased its position in shares of Pfizer by 11.7% during the second quarter. BankPlus Trust Department now owns 64,219 shares of the biopharmaceutical company’s stock worth $1,557,000 after acquiring an additional 6,748 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.